ABSTRACT
PURPOSE: The prevention of postoperative recurrence is a critical issue in surgery for Crohn's disease. Prospective randomized trials in Western countries have shown that the postoperative use of anti-tumor necrosis factor α-antibodies was effective in reducing the recurrence rate. We investigated the efficacy of infliximab (IFX) for the prevention of postoperative Crohn's disease recurrence. METHODS: We performed a prospective randomized multicenter study. Patients who underwent intestinal resection were assigned to groups treated with or without IFX. Immediately after surgery, patients in the IFX group received IFX at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years. The primary study outcome was the proportion of patients with endoscopic and/or clinical recurrence at 2 years after surgery. RESULTS: Thirty-eight eligible patients participated in this study: 19 in the IFX group and 19 in the non-IFX group. The disease recurrence rate in the IFX group was 52.6% (10/19), which was significantly lower than that in the non-IFX group (94.7% [18/19]). CONCLUSION: The postoperative use of IFX is effective in preventing Crohn's disease recurrence for 2 years.
Subject(s)
Crohn Disease/drug therapy , Crohn Disease/surgery , Gastrointestinal Agents/administration & dosage , Infliximab/administration & dosage , Postoperative Care , Secondary Prevention , Adult , Aged , Combined Modality Therapy , Female , Humans , Japan , Male , Middle Aged , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: The prevalence of inflammatory bowel disease (IBD) is increasing. Since patients usually need long-term treatment and suffer from reduced quality of life, there is a need to develop new therapeutic strategy. The aim of this study was to investigate the therapeutic potential of erythropoietin (EPO) for the treatment of IBD. METHODS: Murine colitis was induced by 3.0% Dextran Sulfate Sodium (DSS). Recombinant human EPO (rhEPO) was given to evaluate the anti-inflammatory and regenerative effects on intestinal inflammation. The effect of rhEPO on human colon epithelial cells was also evaluated. Immunohistochemical analysis of EPO receptor was performed in human IBD tissues. RESULTS: While about 62% of control mice with severe colitis induced by 5-day DSS died, 85% of mice treated with rhEPO survived. Histological analysis confirmed that EPO treatment reduced the colonic inflammation. Furthermore, EPO treatment significantly downregulated the local expressions of IFN-γ, TNF-α and E-selectin in the colon, suggesting that the effect was associated with inhibiting local immune activation. In a 4-day DSS-induced colitis model, rhEPO significantly improved the recovery of body weight loss compared to controls. Furthermore, proliferating cell nuclear antigen expression was significantly upregulated in the colon tissue from mice treated with rhEPO compared to controls. In addition, rhEPO increased the growth of cultured human colon epithelial cells in a dose-dependent manner. Furthermore, EPO-receptor expression was confirmed in human IBD colon tissues. CONCLUSION: Three major functions of EPO, hematopoiesis, anti-inflammation and regeneration, may produce significant effects on intestinal inflammation, therefore suggesting that rhEPO might be useful for IBD.
Subject(s)
Cell Proliferation/drug effects , Colitis/chemically induced , Colon/pathology , Cytokines/metabolism , Dextran Sulfate/toxicity , Erythropoietin/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Intestinal Mucosa/physiology , Regeneration/drug effects , Animals , Disease Models, Animal , Humans , Male , Mice , Mice, Inbred BALB CABSTRACT
A 79-year-old woman with symptomatic pyloric stenosis was diagnosed with advanced gastric cancer. CT revealed that the tumor had invaded into the pancreatic head.Since no contraindications were found at laparotomy, we performed pancreatoduodenectomy. The histopathologic diagnosis was pT4b (panc), pN3a (11/35), P0, CY0, H0, M0, pStage â ¢C, R0. The patient received adjuvant chemotherapy with S-1 for 1 year. The patient has survived without recurrence for more than 2 years. The efficacy of pancreatoduodenectomy for advanced gastric cancer is still controversial. Pancreatoduodenetomy may be indicated for selected cases of advanced gastric cancer, if an R0 resection can be achieved.
Subject(s)
Pancreas/surgery , Stomach Neoplasms/surgery , Aged , Antimetabolites, Antineoplastic/therapeutic use , Drug Combinations , Female , Gastrectomy , Humans , Neoplasm Invasiveness , Oxonic Acid/therapeutic use , Pancreas/pathology , Pancreaticoduodenectomy , Stomach Neoplasms/drug therapy , Stomach Neoplasms/pathology , Tegafur/therapeutic use , Time FactorsABSTRACT
In 2010, a newly-created medical fee was established for "Cancer Patient Rehabilitation." We acquired the facility criteria for cancer rehabilitation in August 2011. In December 2005, we started a preventive rehabilitation program to provide comprehensive respiratory physical therapy. Maintenance rehabilitation, palliative rehabilitation and home visiting rehabilitation have been increasing recently. All our staff hope to provide safer, improved skills cancer medical care for all patients by using better rehabilitation skills.
Subject(s)
Neoplasms/rehabilitation , Aged , Female , Hospitals , Humans , Lung Diseases/diagnosis , Male , Middle Aged , Patient Care Team , Postoperative ComplicationsABSTRACT
The current treatment plan for squamous cell anal canal carcinoma using chemoradiotherapy (CRT) is becoming more standardized. We use CRT rather than surgery to select the appropriate treatment. We experienced 4 patients treated with abdominoperineal resection(APR), of which 1 underwent adjuvant CRT. We also experienced 3 patients treated with radiotherapy(RT) and 2 treated with CRT. A patient treated with RT underwent APR because of radiation colitis. RT and CRT are advantageous for quality of life and are expected to be effective for controlling the disease. We hope that the standard treatment plan for anal cancer in Japan will be determined on the basis of histological features.
Subject(s)
Anus Neoplasms/therapy , Carcinoma, Squamous Cell/therapy , Adult , Aged , Aged, 80 and over , Chemoradiotherapy/adverse effects , Female , Humans , Middle AgedABSTRACT
A man in his early seventies underwent low anterior resection and partial resection of the liver for the rectal cancer and liver metastasis. However, 4 months after the surgery, he was found to have a liver tumor at S5 and S7 by abdominal CT scan. Then, he underwent chemotherapy (mFOLFOX6), but the metastatic tumor was progressive. We selected FOLFIRI + cetuximab regimen for second-line therapy to resect the metastatic tumor. As the metastatic lesion was become smaller after 4-course of the regimen including cetuximab, we decided to perform a radical resection. We conducted a right lobectomy of the liver, and the tumor was completely resected.
Subject(s)
Adenocarcinoma/therapy , Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Colonic Neoplasms/pathology , Hepatectomy , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Aged , Antibodies, Monoclonal, Humanized , Camptothecin/administration & dosage , Camptothecin/analogs & derivatives , Cetuximab , Combined Modality Therapy , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , MaleABSTRACT
A woman in her fifties underwent a right hemicolectomy (D3) for cancer of the ascending colon in October 2007, definitively and pathologically diagnosed as papillary adenocarcinoma invading to the subserosa, and no metastasis was detected to lymph node. But 13 months after the surgery, she was found to have a mass near the anastomosis by an abdominal CT scan. Colonoscopy showed an evaluating lesion with ulcer in the anal side of the anastomosis. We tried to resect the metastasis, but it was not resectable because of the invasion to the pancreas. The mFOLFOX regimen was effective. After the chemotherapy (6 courses), we decided to perform a radical resection. We conducted pancreatoduodenectomy in May 2009. She is still alive 12 months after surgery.
Subject(s)
Adenocarcinoma, Papillary/pathology , Adenocarcinoma, Papillary/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colonic Neoplasms/pathology , Colonic Neoplasms/therapy , Lymphatic Metastasis/pathology , Pancreatic Neoplasms/secondary , Pancreatic Neoplasms/therapy , Duodenum/surgery , Female , Fluorouracil/therapeutic use , Humans , Leucovorin/therapeutic use , Middle Aged , Neoplasm Recurrence, Local , Organoplatinum Compounds/therapeutic use , PancreatectomyABSTRACT
INTRODUCTION: Based on previously published papers, the learning curve for laparoscopic groin hernia repair is controversial. The purpose of the present study was to evaluate the learning curve for laparoscopic surgery for groin hernia in a local hospital setting. METHOD: We analyzed 100 consecutive cases of laparoscopic transabdominal preperitoneal repair performed by a single surgeon at a single facility from April 2013 to December 2015. The total operative time was divided into three parts: (a) preparing the peritoneal flap, (b) unfolding the mesh, and (c) suturing the peritoneum. A cumulative sum method for the total operative time and duration of the three parts was used to determine the learning curve. RESULTS: The learning curve was overcome after 75 cases based on cumulative sum analysis of the total operative time. The cumulative sum analysis of the times to unfold mesh and to suture the peritoneum indicated that the learning curve was overcome after 22 and 32 cases, respectively. The learning curve for preparing the peritoneal space was correlated with that for the entire procedure. No cases of recurrence were encountered. CONCLUSION: At least 75 cases were needed to overcome the learning curve for laparoscopic transabdominal preperitoneal repair.
Subject(s)
Hernia, Inguinal/surgery , Herniorrhaphy/education , Laparoscopy/education , Learning Curve , Postoperative Complications/epidemiology , Adult , Aged , Aged, 80 and over , Clinical Competence , Female , Herniorrhaphy/adverse effects , Humans , Laparoscopy/adverse effects , Male , Middle Aged , Operative Time , Retrospective Studies , Surgical Mesh , Suture TechniquesABSTRACT
Transanal intersphincteric resection (ISR) has been increasingly used as a surgical treatment for extremely low rectal cancer. We hypothesized that high quality less invasive surgery could be achieved if ISR and laparoscopic surgery were combined. The patient was a 46-year-old male with advanced rectal cancer on the lower rectum adjacent to the dentate line. The patient refused abdomino-perineal resection (APR), so we performed laparoscope-assisted ISR after preoperative chemotherapy. Previous dissection of this patient facilitated the muscle layer-oriented curative dissection, and more importantly, made the subsequent laparoscopic rectal excision effortless. This patient showed favorable recovery including postoperative anal function with no complications or recurrent disease. This procedure is feasible and has favorable short-term results for the radical treatment of very low rectal disease, while preserving anal function. This operative procedure may be appropriate for locally advanced rectal cancers to avoid a permanent colostomy.
Subject(s)
Adenocarcinoma/surgery , Anal Canal/surgery , Antineoplastic Agents/therapeutic use , Dissection/methods , Laparoscopy , Rectal Neoplasms/surgery , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Humans , Male , Middle Aged , Neoplasm Invasiveness , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathologyABSTRACT
Our hospital fights against a clinical study clearly. However, our hospital did not participate in a clinical study here. When I widened a clinical study in cooperation with the staff, I make a progress report. I started a clinical study only with a doctor first. Therefore it was recognized many problems happened and to promote a clinical study without cooperation of the work of many kinds. I studied with the staff to promote a clinical study and deepened understanding. Thereafter the clinical study was led by a nurse of the chemotherapy room; , in addition, was able to get various cooperation from a skiagrapher. When OGSG0603 began, the nurse and the pharmacist served to become the key than a doctor. I was able to promote a clinical study by cooperation of much staff. In addition, I was able to carry out the system improvement of each section by performing a clinical study.
Subject(s)
Hospitals , Clinical Trials as Topic , Humans , Patient Care TeamABSTRACT
We describe a method for the simultaneous determination of 12 kinds of polycyclic aromatic hydrocarbons (PAHs) in sediment based on liquid chromatography-atmospheric pressure photoionization-mass spectrometry (LC/APPI/MS). The method consists of PAH extractions by ultrasonics, clean-up by a solid-phase extraction procedure and determination by LC/APPI/MS. The limits of the determination for PAHs in sediment using the proposed method ranged from 0.06 to 0.9 mg/kg. PAHs were detected by this method in sediment samples on the mg/kg level.